Proposed explanations include: Tissue retention of peptide or active metabolites Persistent activation of signaling cascades beyond peptide clearance Potential for active metabolites with prolonged tissue residence Excretion Pathways Limited data on elimination routes indicates: Likely renal excretion of peptide fragments based on molecular weight and water solubility Potential hepatic contribution to metabolite clearance No evidence of accumulation in chronic dosing studies in rats and monkeys Degradation products eliminated without evidence of toxic metabolite formation The dramatic disconnect between three-minute plasma half-life and prolonged metabolic effects remains one of the most intriguing and poorly understood aspects of AOD-9604 pharmacology, requiring further mechanistic investigation

Choose AOD9604 if your primary goals are: Targeted Fat Reduction: If your main objective is to specifically target and reduce adipose tissue, particularly stubborn fat, and improve body composition, AOD9604's mechanism of action is more directly focused on these outcomes
This can help restore energy production, reduce oxidative stress, and promote recovery
Please note: Health Coaches are not doctors and cannot prescribe, provide specific medical advice or diagnose you with any medical conditions
Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences
2b), which is subsequently hydrolysed by CSE in the second step to generate cysteine and other compounds (e.g